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ABSTRACT 
Abnormal Wnt signaling is associated with bone mass disorders (Westendorf J. et al., 2004). Frizzled 
related protein (FRZB, also known as secreted frizzled-related protein-3 (SFRP3)) is a Wnt modulator 
that contains an amino-terminal cysteine-rich (CRD) domain and a carboxy-terminal Netrin-like (NTN) 
motif (Cruciat C., et al., 2013). Frzbí/í mice show increased cortical thickness (Lories R., et al., 2007). 
However, the direct effect of FRZB on osteogenic differentiation and the involvement of the structural 
domains herein is not fully understood. In this study, we observed that stable overexpression of Frzb in 
MC3T3-E1 cells increased calcium deposition and osteoblast markers compared to control.  Western blot 
analysis showed that the increased osteogenesis was associated with reduced canonical, but increased 
non-canonical Wnt signaling. On the contrary, loss of Frzb induced the opposite effects on osteogenesis 
and Wnt signaling. To translationally validate the positive effects of FRZB on primary human cells, we 
treated human periosteal and human bone marrow stromal cells with conditionned medium from MC3T3-
E1 cells overexpressing Frzb and observed an increase in Alizarin red staining. We further studied the 
effect of the domains. FrzbNTN overexpression induced similar effects on osteogenesis as full length Frzb, 
whereas FrzbCRD overexpressing cells mimicked loss of Frzb experiments. The CRD domain is considered 
the Wnt binding domain, but the NTN domain also has important effects on bone biology. FRZB and 
other SFRPs or their specific domains may hold surprising potential as therapeutics for bone and joint 
disorders considering that excess of SFRPs has effects that are not expected under physiological, 
endogenous expression conditions.  
 
List of abbreviations:  
alkaline phosphatase (ALP); antibiotic- antimycotic (AB); calcium-calmodulin-dependent kinase II 
(CamKII); conditioned medium (CM); cysteine-rich domain (CRD); Frizzled (Fz); Frizzled related 
protein (FRZB); human bone marrow stromal cells (hBMSCs); hypoxanthine guanine phosphoribosyl 
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transferase1 (Hprt1); human periosteum-derived cells (hPDCs); Netrin-like (NTN); secreted frizzled 
related protein (SFRP); tissue inhibitors of metallo-proteinases (TIMPs); type I procollagen C-proteinase 
enhancer proteins (PCOLCEs) 
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The Wnt signaling pathway is a key regulator of development, tissue growth, homeostasis and disease. 
Animal models and human genetic syndromes link abnormal Wnt signaling with high and low bone mass 
(1, 2). The Wnt family is a large group of lipid-modified secreted glycoproteins. Mammals have 19 Wnt 
homologs composed of 350 to 400 amino acids that share an N-terminal signal sequence for secretion 
followed by a nearly invariant pattern of 22-24 cysteines and several N-glycosylation sites (3, 4). Wnts 
are palmytoylated intracellularly by the enzyme porcupine. The presence of the lipid side chain affects 
solubility and signaling range.  
Active Wnt signaling typically involves the canonical or ȕ-catenin dependent cascade. In the absence of 
Wnt ligand, Frizzled (Fz) receptor and low-density lipoprotein receptor-related protein-5/6 coreceptor 
interaction, ȕ-catenin is caught in a molecular destruction complex, phosphorylated and degraded by the 
proteasome. Upon Wnt-receptor interaction, the destruction complex is tethered away towards the 
receptor complex or disassembles, ȕ-catenin accumulates in the cell, translocates to the nucleus and 
associates with transcription factors of the T-cell factor/lymphoid enhancer factor family. Wnts also 
signal through ȕ-catenin-independent pathways. The planar cell polarity pathway activates GTPases of 
the RHO family and c-Jun N-terminal kinase to regulate the cytoskeleton and cell polarity, while the 
Wnt/Ca2+ pathway stimulates heterotrimeric G proteins, intracellular calcium release and activation of 
various calcium-sensitive enzymes such as protein kinase C, calcium-calmodulin-dependent kinase II 
(CamKII) and phosphatase calcineurin (3, 5). 
The secreted frizzled related protein (SFRP) -family comprises five secreted molecules (SFRP1-5) and 
can modulate both canonical and non-canonical Wnt cascades.  Every SFRP contains an amino-terminal 
cysteine-rich (CRD) domain and a carboxy-terminal Netrin-like (NTN) motif. The CRD domain shares 
structural homology with the Fz receptor and is therefore considered the Wnt binding domain. The NTN 
domain shows homology to the axonal guidance protein Netrin and is also found in tissue inhibitors of 
metallo-proteinases (TIMPs), complement proteins and type I procollagen C-proteinase enhancer proteins 
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(PCOLCEs). Until now, the exact role of the NTN domain in SFRP function remains unclear (6, 7). 
SFPRs were originally identified as extracellular ligand-binding inhibitors of the Wnt signaling cascade. 
Recent data suggest that SFRPs have a broad range of biological activities, including negative and 
positive modulation of Wnt signaling (8, 9) and interactions with molecules unrelated to Wnt signaling 
(7). Deletions of Frizzled-related protein (Frzb (Sfrp3)) in mice leads to increased cortical thickness 
without changes in the trabecular bone (10). Here, we aimed to directly assess the effect of FRZB on 
osteogenic differentiation and to elucidate the involvement of the CRD and NTN domain. .  
 
MATERIALS AND METHODS 
Molecular constructs  
The pcDNA3.1-full length Frzb, pcDNA3.1- Frzb ǼCRDAA39-145 (7C) (referred to as FrzbNTN) and 
pcDNA3.1-Frzb ǼNTNAA160-316 (referred to as FrzbCRD) constructs were earlier described (11). 
Cell culture 
Human periosteum-derived cells (hPDCs) and hBMSCs (a kind gift from C. Verfaillie, KU Leuven) were 
isolated as described earlier (12, 13). HPDCs, hBMSCs and MC3T3-E1 cells were cultured in 
maintenance medium DMEM (Gibco, Merelbeke, Belgium) containing 10% fetal bovine serum (FBS, 
Gibco), 1% antibiotic-antimycotic (AB, Invitrogen, Merelbeke, Belgium) and 1% sodium pyruvate (SP, 
Invitrogen). 
Generation of stably transfected MC3T3-E1 cell lines  
MC3T3-E1 cells were transfected with control pcDNA3.1+, pcDNA3.1-Frzb, pcDNA3.1-FrzbCRD or 
pcDNA3.1-FrzbNTN constructs using lipid-based agent Fugene HD (Roche Diagnostic, Vilvoorde, 
Belgium). Selection was initiated 24 hours after transfection by supplementing the maintenance medium 
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with 0.1 mg/ml geneticin (Invitrogen) for pcDNA3.1-FrzbCRD and 1 mg/ml for all other constructs. Clones 
were picked after 14 days of selection. Three different antibiotic-resistant clonal colonies of each 
condition were isolated and grown independently. Overexpression levels were assessed by quantitative 
RT-PCR (Q-PCR). Silencing of Frzb was performed using a pGIPZ-shmiRNA construct directed against 
mouse Frzb (Thermo Scientific, Aalst, Belgium) and a non-interfering pGIPZ vector (Thermo Scientific) 
was used as control. MC3T3-E1 cells were transfected using Arrest-In transfection reagent (Thermo 
Scientific) and after 24 hours, seletion with 1 ȝg/ml puromycin (Invitrogen) was initiated and continued 
for 7 days. Three different antibiotic-resistant clonal colonies of each condition were isolated and grown 
independently. Knockdown efficiency was assessed by Q-PCR. Antibiotic pressure was maintained for 
the whole duration of the experiments.  
 
Osteogenic differentiation  
Stably transfected MC3T3-E1 cells were seeded at 2.5 x 104 cells/well in 6-well culture plates (Thermo 
Scientific) in maintenance medium. At day 1, medium was changed to differentiation medium (Į-
Minimum Essential Medium Eagle (Į-MEM) (Gibco) containing 10% FBS, 1% AB, 10 mM ȕ-
glycerophosphate and 50 ȝg/ml L-ascorbic acid-2-phosphate). The medium was refreshed every other day 
for 21 days. HPDCs were seeded at 1.5 x 104cells/well in 12-well culture plates (Thermo Scientific, Nunc) 
in maintenance medium. At day 1, medium was changed to differentiation medium consisting of Į-MEM 
supplemented with 10% FBS, 1% AB, 10 mM ȕ-glycerophosphate, 50 ȝg/ml L-ascorbic acid-2-phosphate 
and 0.1 nM dexamethasone (Sigma-Aldrich, Bornem, Belgium). Medium was changed every other day 
for 28 days of differentiation. Cells were stored at different time points for Alizarin red staining, RNA, 
protein extraction and alkaline phosphatase (ALP) activity assay. All conditions were performed in 
triplicate. For competition experiments with recombinant mFrzb, the differentiation medium was 
supplemented with 100 ng/ml recombinant mFrzb (RnD systems) for 14 days. For experiments under the 
stimulation of canonical or non-canonical Wnts, we treated the MC3T3-E1 cells with 100 ng/ml 
recombinant mWnt3a (RnD systems) or mWnt5a (RnD systems) during 14 days of differentiation. 
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Conditioned medium (CM) experiment  
Supernatant (referred to as CM) was harvested every other day from confluent T75 culture flasks of 
MC3T3-E1 cells stably transfected with pcDNA3.1+ control vector or pcDNA3.1-Frzb.  The supernatant 
was cleared by centrifugation at 3500 rpm for 10 min, and supplemented with 10 mM ȕ-glycerophosphate 
and 50 ȝg/ml L-ascorbic acid-2-phosphate. Cells stably transfected with pcDNA3.1+ were seeded and the 
medium was refreshed every other day with differentiation medium enriched with supplemented CM in a 
2:1 v/v ratio. At day 1 and 21 cells were stored for Alizarin red staining and ALP activity assay. For 
hPDCs and hBMSCs differentiation with CM, the medium was refreshed every other day with 
differentiation medium enriched with supplemented CM derived from MC3T3-E1 cells stably transfected 
with pcDNA3.1+ control vector or pcDNA3.1-Frzb. The supernatant was cleared by centrifugation at 3 
500 rpm for 10 min and supplemented with 10 mM ȕ-glycerophosphate, 50 ȝg/ml L-ascorbic acid-2-
phosphate and 0.1 nM dexamethasone. The medium was refreshed every other day with differentiation 
medium enriched with supplemented CM in a 2:1 v/v ratio. At day 1 and 28 cells were stored for Alizarin 
red staining. Each condition was performed in triplicate. 
 
Western blot analysis  
MC3T3-E1 cells were harvested and resuspended in 0.05% Triton X (AppliChem, Zedelgem, Belgium) in 
PBS (Lonza, Verviers, Belgium) supplemented with 1 mM phenylmethanesulfonyl (Sigma-Aldrich), 5% 
protease inhibitor cocktail (Sigma-Aldrich), 2.3 mM Na3VO4 (Sigma-Aldrich) and 5 mM NaF (Merck 
Millipore, Overijse, Belgium). Cell lysates were sonicated (2 cycles of 7 s) and centrifuged at 13 000 rpm 
for 10 min, followed by protein quantification using the Pierce BCA Protein Assay kit (Thermo 
Scientific). A total of 7.5 ȝg of protein of each sample was denatured and separated on a 4-12% 
polyacrylamide Bis-Tris gel (Invitrogen) by electrophoresis using NuPage MES SDS Running buffer 
(Invitrogen). Proteins were transferred to a PVDF membrane (Merck Millipore). Non-specific binding 
sites were blocked using 5% non-fat milk in Tris-buffered saline with 0.1% Tween (Applichem) (TBS/T) 
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for one hour at room temperature. Primary antibodies were incubated overnight at 4°C with the following 
antibodies: 1/1 000 active- (dephosphorylated) ȕ-catenin (CTNNB1) mouse antibody (Millipore), 1/1 000 
total ȕ -catenin mouse antibody (BD Biosciences, Aalst, Belgium), 1/1 000 anti- pCamK rabbit antibody 
(Cell Signaling Technology, Leiden, The Netherlands), 1/1 000 anti-CamK (pan) rabbit antibody (Cell 
Signaling Technology), 1/1000 anti-pCREB antibody (Cell Signaling Technology), 1/1000 anti-CREB 
antibody (Cell Signaling Technology) and 1/7500 anti-actin rabbit antibody (housekeeping gene; Sigma-
Aldrich) in 5% bovine serum albumin in TBS/T (Cell Signaling Technology). Secondary horseradish 
peroxidase -conjugated antibodies were added and blots were developed using SuperSignal West Femto 
Maximum Sensitivy Substrate (Pierce, Thermo Scientific). Densitometry of blots was performed using 
Image J software (version 1.46r, National Institutes of Health) (Supplementary Table 1 and 2).  
 
qPCR
Total RNA was isolated using NucleoSpin RNAII kit (Machery-Nagel, Düren, Germany) following the 
manufacturer’s protocol. Complementary DNA was synthesized from 0.5-1 ȝg of total RNA using the 
RevertAid H minus First Strand cDNA synthesis kit (Fermentas GmbH, Rockford, IL USA). The 
SYBRgreen master mix system (Fermentas GmbH) was used to verify differential expression of bFrzb, 
mFrzb, Osterix, Osteocalcin and Axin2 (Table 1).  SYBRgreen quantitative analysis was performed on the 
Corbett Rotor-Gene 6000 (Corbett Research, Westburg, Leusden, The Netherlands) as follows: 10 
minutes at 95°C, 40 cycles of 15 seconds of denaturation at 95°C, followed by 60 seconds of annealing-
extension at 60°C. Melting curve analysis was performed to ensure amplification of a specific product. 
Results are expressed using the comparative threshold method (14) and normalised to housekeeping gene 
Hprt1 (hypoxanthine guanine phosphoribosyl transferase1).  
 
ALP activity
Cells were resuspended in 0.05% Triton X in PBS and sonicated (2 cycles of 7 s). ALP activity was 
measured using the BluePhos® Microwell Phosphatase Substrate System (KPL, Gaithersburg, Maryland 
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USA) following the manufacturer’s instructions. Absorbance was measured at 495nm with a Titertek Plus 
MS212 microplate reader (Tecan, Mechelen, Belgium). When absorbance reached the saturation level, 
samples were diluted 1 in 3 in 0.05% Triton X in PBS.  
 
Alizarin red staining and quantification  
At day 1, 7, 14 and 21, cells were washed with PBS and fixed with ice cold 95% methanol for 30 min. 
Next, cells were washed with water and stained with 1% Alizarin Red (Sigma-Aldrich) at pH 4.1-4.3 for 
10-15 min. 3 washing steps with water removed the unbound staining solution. Stains were dissolved in 
10% acetic acid for 30 min. Cells were scraped off the culture plates, vortexed and heated for 10 min at 
85°C. After 5 min on ice, the solution was centrifuged at 13 000 rpm for 15 min at 4°C. 10% ammonium 
hydroxide was added to the aqueous phase in a 1:5 v/v ratio. Absorbance was measured at 405nm with a 
Biotek Synergy HT microplate reader. When absorbance reached the saturation level, samples were 
diluted 1 in 3 in a mixture of 10% acetic acid and 10% ammonium hydroxide (1:5 v/v ratio). The 
mineralization nodules in the hPDCS and hBSMCs CM experiments were quantified using Image J 
software (NIH).  
 
Statistics
Data were analyzed by 2-way ANOVA taking into account repeated measurements as observations over 
time could not be considered independent. Time and Frzb expression were defined as factors. The overall 
effect of both factors and their interaction was evaluated. Post-hoc Sidak tests were applied for the 
different time-points when interaction between time and target gene expression was found. Alpha was set 
at 0.05. 
 
 
RESULTS 
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Overexpression of Frzb increases osteogenesis  
We studied the effects of FRZB on differentiation and mineralization in MC3T3-E1 cells, a mouse 
calvarial osteoblast precursor cell line. Stably transfected MC3T3-E1 cells were used and high expression 
levels of Frzb were sustained throughout the 21-day experiments (average fold increase compared to 
control 3.5*103) (Figure 1A). Overexpression of Frzb resulted in significantly enhanced Alizarin red 
staining (2-way ANOVA p < 0.0001 for interaction between time and Frzb overexpression – p < 0.05 
between control and overexpression at day 14 and 21, but not day 1 and 7, with difference between means 
respectively -4.8 (95%CI: -5.5; -4,2) for day 14 and -12.4 (95%CI: -13.0; 11.8) for day 21 (Sidak test)) 
(Figure 1 A-B) and significantly increased ALP activity compared to control (2-way ANOVA p < 0.0001 
for interaction between time and Frzb overexpression – p < 0.05 between control and overexpression at 
day 1, 7, 14 and 21, with difference between means respectively -3.2 (95%CI: -6.0;-0.5) for day 1, -9.9 
(95%CI: -12.6;-7.1) for day 7, -14.2 (95%CI: -16.9;-11.4) for day 14 and -7.3 (95%CI: -10.0;-4.5) for day 
21 (Sidak test)) (Figure 1 C). Similar results were obtained with two additional and independent clones. 
Treatment of control MC3T3-E1 cells with conditioned medium (CM) from Frzb overexpressing cells 
increased both Alizarin Red staining (unpaired t-test p=0.007) (Figure 1 D-E) and ALP activity (unpaired 
t-test p=0.03) (Figure 1 F) at day 21.   
 
Overexpression of Frzb modulates Wnt signaling and osteogenic differentiation 
SFRPs were originally identified as inhibitors of Wnt signaling. Overexpression of Frzb decreased both 
active and total ȕ-catenin. In contrast, Frzb overexpression increased the total amount and 
phosphorylation of CamKII and phosphorylated CREB, which is a downstream target of CamKII (Figure 
2 A). This suggests a negative effect on canonical signaling, but a positive effect on the non-canonical 
Wnt/Ca2+ pathway.  
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Frzb overexpression decreased levels of Axin2, a known target gene in the canonical Wnt cascade (2-way 
ANOVA p = 0.0029 for interaction between time and Frzb overexpression – p < 0.05 between control and 
overexpression at day 14 and 21, with difference between means respectively 36.7 (95%CI: 19.3; 54.0) 
for day 14 and 28.9 (95%CI: 11.5; 46.2) for day 21 (Sidak test)) (Figure 2 B). Gain of Frzb increased 
expression of osteoblast-specific transcription factors Osterix (2-way ANOVA p < 0.0001 for interaction 
between time and Frzb overexpression – p < 0.05 between control and overexpression at day 7, 14 and 
21, with difference between means respectively -446.5 (95%CI: -658.5; -234.6) for day 7, -899.0 (95%CI: 
-1111; -687.1) for day 14 and -624.5 (95%CI: -836.4; -412.6) for day 21 (Sidak test)) and Osteocalcin (2-
way ANOVA p < 0.0001 for interaction between time and Frzb overexpression – p < 0.05 between 
control and overexpression at day 14 and 21, with difference between means respectively -12364 (95%CI: 
-16444;-8284) for day 14 and -52075 (95%CI: -56155;-47995) for day 21 (Sidak test)) (Figure 2 B). 
Similar data were obtained in two additional experiments and for two other, independent cell lines 
overexpressing Frzb..  
 
Loss of Frzb negatively affects osteogenesis 
Silencing of endogenous Frzb throughout the 21-day experiment was obtained by a pGIPZ-shRNAmir 
plasmid directed against Frzb (32%, 47%, 95% and 97% knockdown at day 1, 7, 14 and 21). Loss of Frzb 
decreased Alizarin red staining at day 14 and day 21 (2-way ANOVA p = 0.02 for interaction between 
time and Frzb silencing – p < 0.05 between control and silencing at day 14 and 21, with difference 
between means respectively 0.6637 (95%CI: 0.1; 1.2) for day 14 and 0.8520 (95%CI:0.3; 1.4) for day 21 
(Sidak test)) (Figure 3 A-B) and reduced ALP activity (2-way ANOVA p <0.0001 for interaction between 
time and Frzb silencing – p < 0.05 between control and silencing at day 14 and 21, with difference 
between means respectively 3.6 (95%CI: 3.3;3.9) for day 14 and 8.358 (95%CI:8.0;8.7) for day 21 (Sidak 
test)) (Figure 3 C) compared to control shRNAmir. Decreased Frzb levels showed a reverse effect 
compared to overexpression on canonical and non-canocial cascades (Figure 3 D). Loss of Frzb reduced 
expression of Osterix  (2-way ANOVA p < 0.0001 for interaction between time and Frzb silencing – p < 
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0.05 between control and silencing at day 14 and 21, with difference between means respectively 13.7 
(95%CI: 9.4; 17.9) for day 14 and 18.2 (95%CI: 13.9; 22.4) for day 21 (Sidak test)) and Osteocalcin (2-
way ANOVA p < 0.0001 for interaction between time and Frzb silencing – p < 0.05 between control and 
silencing at day 21, with difference between means respectively 412.3 (95%CI: 346.0;478.6) for day 21 
(Sidak test)), but did not affect Axin2 expression (Figure 3 E). Similar data were obtained in an additional 
experiment and for an other, independent cell line with loss of Frzb.. 
 
Validation in primary human periosteal cells (hPDCs) and human bone marrow stromal cells 
(hBMSCs) 
To translationally validate the positive effects of FRZB on primary human cells, we used hPDCs and 
hBMSCs, cell types with strong osteogenic potential. Treatment of hPDCs and hBMSCs with CM from 
MC3T3-E1 cells overexpressing Frzb increased Alizarin red staining at day 28 (unpaired t-test p=0.03 
and p=0.02) (Figure 4).  
 
FrzbNTN overexpression mimics full length Frzb overexpression in osteogenesis  
We further studied the effect of the CRD domain and NTN motif in our assays. Sustained high expression 
of the FrzbNTN domain (average fold increase compared to control 3.1*103) increased Alizarin red staining 
(2-way ANOVA p < 0.0001 for interaction between time and Frzb overexpression – p < 0.05 between 
control and overexpression at day 14 and 21, with difference between means respectively -10.6 (95%CI: -
11.8; -9.3) for day 14 and -25.5 (95%CI: -26.8; -24.2) for day 21 (Sidak test)) (Figure 5 A,C) and ALP 
activity (2-way ANOVA p < 0.0001 for interaction between time and Frzb overexpression – p < 0.05 
between control and overexpression at day 1, 7, 14 and 21, with difference between means respectively -
2.1 (95%CI: -2.8; -1.5) for day 1, -3.9 (95%CI: -4.5; -3.3) for day 7, -4.3 (95%CI: -4.9; -3.7) for day 14 
and -9.6 (95%CI: -10.2;-9.0) for day 21 (Sidak test)) (Figure 5 D). Additionally, gain of FrzbNTN 
increased Osterix expression at day 7 (2-way ANOVA p = 0.04 for interaction between time and Frzb 
overexpression – p < 0.05 between control and overexpression at day 7 with difference between means 
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respectively -132.0 (95%CI: -233.6; -30.5) for day 7 (Sidak test)) (Figure 5 E). Similar data were obtained 
in two additional experiments and for two other, independent cell lines overexpressing FrzbNTN. 
Treatment of hBMSCs with CM from MC3T3-E1 cells overexpressing FrzbNTN increased Alizarin red 
staining at day 28 (unpaired t-test p=0.01) (Figure 5 B). On the contrary, overexpression of the FrzbCRD 
(average fold increase compared to control 75) domain slightly decreased Alizarin red staining (2-way 
ANOVA p = 0.0007 for interaction between time and Frzb overexpression – p < 0.05 between control and 
overexpression at day 7 and 21, with difference between means respectively 0.2  (95%CI: 0.09; 0.3) for 
day 7 and 0.1 (95%CI: 0.0002;0.2) for day 21 (Sidak test))  (Figure 5 F,H) and ALP activity (2-way 
ANOVA p < 0.0001 for interaction between time and  Frzb overexpression – p < 0.05 between control 
and overexpression at day 14 and 21, with difference between means respectively 7.0 (95%CI: 6.1;7.9) 
for day 14 and 5.2 (95%CI: 4.3;6.1) for day 21 (Sidak test)) (Figure 5 I). Moreover, the FrzbCRD domain 
did not consistently alter Osterix expression (Figure 5 J). Similar data were obtained in two additional 
experiments and for two other, independent cell lines overexpressing FrzbCRD. FrzbNTN overexpression 
decreased active ȕ-catenin and increased phosphorylated CamKII at day 21, while FrzbCRD 
overexpression decreased both active and total ȕ-catenin throughout the whole experiment and decreased 
phosphorylated CamKII at day 21 (Figure 6 A-B). Treatment of hBMSCs with CM from MC3T3-E1 cells 
overexpressing FrzbCRD decreased Alizarin red staining at day 28 (unpaired t-test p<0.0001) (Figure 5 G).  
Interaction of FrzbNTN and FrzbCRD with full length Frzb and Wnts  
The observations reported above could indicate that FrzbNTN and FrzbCRD have a dominant-negative effect 
on the full-length protein. To further investigate potential competition of the overexpressed domains with 
the full length protein, we treated MC3T3-E1 cells control cells and cells overexpressing FrzbNTN or 
FrzbCRD with recombinant mFrzb for 14 days. Adding recombinant FRZB to the differentiation culture 
slightly but significantly increased Alizarin Red staining in FrzbNTN overexpressing cells without a similar 
increase in ALP activity. In contrast, we did not detect a difference in Alizarin Red staining and ALP 
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activity for control and FrzbCRD overexpressing cells after treatment with recombinant FRZB 
(Supplementary Figure 1A-C). 
 
Next, we also studied the interactions between exogenously added Wnts and FRZB overexpressing cells. 
Wnt3a decreased Alizarin red staining in cells overexpressing Frzb and FrzbNTN+ and decreased ALP 
activity in control cells and overexpressing Frzb. For Wnt5a, we could observe a decrease in Alizarin red 
staining for cells overexpressing Frzb, but we detected no differences in ALP activity (Supplementary 
Figure 2A-C). Moreover, treatment of MC3T3-E1 with recombinant mWnt3a resulted in an increase in 
active beta-catenin and phosphorylated CamKII in cells overexpressing Frzb and FrzbNTN, but in a 
decrease in canonical Wnt signaling in control cells. Addition of recombinant mWnt5a only positively 
influenced canonical Wnt signaling in cells overexpressing Frzb (Supplementary Figure 2 D).. 
 
 
DISCUSSION 
In our experiments, Frzb overexpression in vitro stimulated osteogenesis and was associated with reduced 
canonical and increased non-canonical Wnt signaling. On the other hand, loss of Frzb decreased 
osteogenesis. This observed positive effect on osteogenesis appears in line with earlier in vitro data 
suggesting that recombinant Frzb increased osteoblast differentiation (15). However, these and our results 
appear contradictory to in vivo data showing that Frzbí/í mice have increased cortical bone thickness (10)  
but not trabecular bone thickness and with the well-known observation that excess of Wnt signaling 
results in high bone mass phenotypes in mice and men (16-21). Other Wnt antagonists have also been 
shown to negatively affect bone formation. Genetic deletion of Sfrp1 in mice leads to an increased 
trabecular bone, while overexpression of SFRP1 inhibits bone formation (22-24). Furthermore, Sfrp1 acts 
as a negative regulator of human osteoblast and osteocyte survival and may also inhibit osteoclastogenesis 
by a Wnt-independent mechanism (22). Sfrp4 also negatively affects bone formation and SFRP4 was also 
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proposed to be involved in phosphate metabolism, but others could not confirm this link (25, 26). 
Additionally, loss of sclerostin (SOST) expression in bone was found to result in Van Buchem disease 
(27). In mice, targeted deletion of Sost results in increased bone formation and strength, while mice 
overexpressing Sost have low bone mass and decreased bone strength (28-30). Another Wnt antagonist, 
DKK1, regulates bone mass with increased expression linked to osteopenia and decreased expression 
associated with HBM (31). Dkk1 knockout mice are embryonic lethal, however, an allelic series of mice 
with decreased DKK1 expression levels (Dkk1+/+, Dkk1+/d, Dkk1+/í and Dkk1d/í) show that for both the 
trabecular and the cortical bone, bone mass is inversely proportional to the level of DKK1 (31). 
Interestingly, Dkk2, like Frzb, positively influences the formation of mineralized matrix in the late stages 
of osteogenic differentiation and this effect might not be entirely mediated by its Wnt signaling 
antagonistic activity (32). We hypothesize that this surprising contrast between in vitro and in vivo 
observations can be explained by the high and therefore supraphysiological levels of the Wnt modulator. 
This overexpression may affect the protein’s biological effects in different ways. Moreover, high local 
concentrations may be achieved in vivo in specific compartments of the skeleton but more importantly 
could be the goal of a treatment strategy. Frzb expression levels significantly increase during osteogenesis 
of MC3T3-E1 cells (Supplementary Figure 3), suggesting that Frzb plays an important role in the later 
stages of osteogenesis and mineralisation. This is in line with the expression profile of Dkk1, Dkk2, 
Sclerostin and SFRP1, also Wnt inhibitors, during osteogenic differentiation (22, 32-34). Interestingly, 
while Sfrp1, Dkk1 and Sclerostin inhibit osteogenesis Dkk2 overexpression shows a similar effect as Frzb 
(33, 34). 
 
Excess of canonical Wnt signaling results typically in high bone mass phenotypes in mice and men (16-
21). However, in our gain of function studies, we observed a decrease in canonical Wnt signaling together 
with augmented osteogenesis and activation of the non-canonical Wnt/CamKII pathway. Although the 
effects of FRZB on osteogenesis can be mediated in part by its Wnt-inhibiting effect, we consider that the 
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role of FRZB in osteoblast differentiation is not limited to its Wnt-antagonistic effect. First, our data 
suggest that canonical Wnt signaling is not the only mediator to drive osteogenesis in this in vitro system. 
The increase of osteogenesis could, at least partly, be caused by an increase of non-canonical Wnt 
signaling. Ca2+ signaling and Ca2+ transport play key roles during osteoblast differentiation and bone 
formation. Many of the cellular effects of Ca2+ are mediated by the Ca2+ binding protein, Calmodulin 
(CaM). Activation of CaM activates in turn both CamKII and CaN (35). Zayzafoon et al. showed that 
inhibition of αCamKII results in a decrease in osteoblast differentiation (36). Additionally, CamKII can 
stimulate osteoblastogenesis by modulating the activity of Osterix, a transcription factor essential for 
osteoblast differentiation and bone mineralization, and Dlx5, that mediates the transcriptional control by 
many osteoblastogenic signaling pathways (37, 38). 
 
Secondly, although SFRPs were originally identified as soluble Wnt inhibitors that bind directly to Wnts 
and prevent their interaction with Fz receptors. However, different biochemical and crystallographic data 
suggested that SFRPs could both activate and inactivate Wnt signaling. SFRPs and Fz receptors have 
been shown to form homodimers and heterodimers via their CRD domains and subsequently stimulate 
signal transduction (7). In our experimental setting Frzb overexpression inhibited canonical Wnt 
signaling, but stimulated non-canonical Wnt/Ca2+ signaling, by increasing both phosphorylated and total 
CamKII. Direct effects of modulator-receptor interaction therefore provide a possible explanation for our 
observations and require further research. Of note, Nalesso et al. demonstrated that distinct Wnt pathways 
are reciprocally inhibitory and in equilibrium and therefore selective inhibition of the canonical pathway 
enhances the activation of the Ca2+ mobilization (39). SFRPs have different binding affinities for distinct 
Wnt ligands (40). Canonical and noncanonical signaling pathway activation involves the shared use of the 
same Fz receptors. Therefore, excess of either type of Wnt might interfere with the other pathway as a 
result of ligand competition for binding to Fz (41). Thirdly, SFRPs can interfere with protease activity 
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(42), interact with proteins which are not directly involved in the Wnt signaling cascade and affect BMP 
signaling (7, 42-45).  
 
FrzbNTN overexpression induced similar effects on osteogenesis as full length Frzb, whereas FrzbCRD 
overexpressing cells mimicked loss of Frzb experiments. The CRD domain of Sfrps is considered the 
Wnt binding domain and is therefore most studied. Nevertheless, our data indicate that the NTN domain 
can also have strong effects on bone differentiation. Both the CRD and NTN domain are required for Wnt 
binding in Drosophila (9). We cannot exclude that the NTN domain has a role in Wnt binding. Earlier 
work found SNPs in the NTN domain associated with hip osteoarthritis (46). Additional data in this paper 
demonstrated that these variants in the NTN domain resulted in reduced Wnt antagonistic activity for the 
full length molecule. In addition, Wnt-binding may not fully explain the observation that overexpression 
of FrzbNTN or FrzbCRD resulted in a different outcome. The NTN domain shows sequence similarity to 
Netrin, TIMPs and PCOLCEs. In TIMPs and PCOLCEs, the NTN domain is thought to interfere with 
protease activity. The SfrpNTN domain may also have protease inhibitory activity (47). For example, 
SFRP2 can act as a procollagen C proteinase enhancer of Tolloid-like metalloproteinases in myocardial 
infarction-associated fibrosis (48), SFRP1 can act as an inhibitor of the A Disintegrin and 
metalloproteinase domain-containing protein 10 metalloprotease (49), Sizzled, a non-mammalian Sfrp 
family member, stabilizes Chordin by binding and inhibiting the Tolloid-family metalloproteinase, 
Bmp1a (43). Thus, even in a relatively straightforward in vitro setting FRZB and other SFRPs may have 
more complex biological effects than anticipated upon their discovery and initial functional assessment.
Although the use of stable cell lines is interesting from a practical point of view, this approach also has 
limitations. The exposure of the cells through their expansion to high levels of FRZB or modified forms 
of the molecule may affect their behavior in the described experiments. We also tested whether the 
mutated forms would have dominant-negative effects and how they interact with Wnt ligands. However, 
adding FRZB to FRZBNTN overexpressing cells has a small but significant positive effect and not a 
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competitive effect on osteogenesis. Wnt3a and Wnt5a do not seem to be able to interact with CRD 
domain without the NTN domain. However, FRZB and the FRZBNTN appear to antagonize the inhibitory 
effect of Wnt3a on osteogenic differentiation.  
 
In summary, our observation that overexpression of Frzb promotes bone differentiation and shifts 
balances between Wnt signaling cascades provides novel perspectives on the Wnt signaling pathway as a 
therapeutic target for bone and joint diseases. SFRPs or their specific domains may hold potential as 
therapeutics taking into account that our strong gain and loss of function approaches highlight that excess 
of SFRPs has effects that are not expected under physiological, endogenous expression conditions. 
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TITLES AND LEGENDS TO FIGURES 
Figure 1: Overexpression of Frzb increases osteogenesis and this effect is induced by secreted 
factors. (A) Alizarin red (AR) staining of MC3T3-E1 cells overexpressing Frzb (Frzb+) compared to 
controls. (B) Quantification of the AR staining of 1 in 3 diluted samples. Data are expressed as relative 
absorbance compared control to cells at the same timepoint. (2-way ANOVA p < 0.0001 for interaction 
between time and Frzb overexpression – *p < 0.05 between control and overexpression) (C) Alkaline 
phosphatase (AP) activity of MC3T3-E1 cells overexpressing Frzb compared to controls. (2-way 
ANOVA p < 0.0001 for interaction between time and Frzb overexpression – *p < 0.05 between control 
and overexpression). Data (A-C) show mean±SD of three replicates, but similar data were obtained in two 
additional experiments and for two other, independent cell lines overexpressing Frzb.. MC3T3-E1 cells 
were stimulated with conditioned medium (CM) from Frzb overexpressing cells. (D) Alizarin red (AR) 
staining (E) Quantification of the AR staining. Data are expressed as the mean absorbance. Unpaired t-
test *p=0.007.  (F) Alkaline phosphatase activity. Unpaired t-test *p=0.03. Data presented (D-F) are 
representative of two independent experiments with CM and show mean±SD of three independent 
replicates. 
Figure 2: Overexpression of Frzb stimulates osteogenesis by decreasing canonical but stimulating 
non-canonical signaling. Western blot analysis shows a decrease in active (dephosphorylated) ȕ-catenin 
(92 kDa) and an increase in phosphorylated CamKII (50 kDa), total CamKII (50 kDa) and phosphorylated 
CREB (43 kDa) in Frzb (A) overexpressing cells. (B) mRNA expression levels of Osterix (2-way 
ANOVA p < 0.0001 for interaction between time and Frzb overexpression – *p < 0.05 between control 
and overexpression), Osteocalcin (2-way ANOVA p < 0.0001 for interaction between time and Frzb 
overexpression – *p < 0.05 between control and overexpression) and Axin2 (2-way ANOVA p = 0.0029 
for interaction between time and Frzb overexpression – *p < 0.05 between control and overexpression) in 
MC3T3-E1 cells stably overexpressing Frzb (Frzb+). All mRNA levels were normalized to Hprt1 
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(reference gene) and shown as relative expression levels compared to control (D1). Data (A-B) show 
mean±SD of three replicates, but similar data were obtained in two additional experiments and for two 
other, independent cell lines overexpressing Frzb.. 
Figure 3: Knockdown of Frzb reduces osteogenesis. (A) Alizarin red (AR) staining of MC3T3-E1 cells 
in which Frzb is stably knocked down (FrzbKD) compared to controls. (B) Quantification of the AR 
staining. Data are expressed as relative absorbance compared to control cells at the same timepoint. (2-
way ANOVA p = 0.01 for interaction between time and Frzb silencing – *p < 0.05 between control and 
silencing) (C) Alkaline phosphatase activity of FrzbKD cells compared to control at day 1. (2-way 
ANOVA p <0.0001 for interaction between time and Frzb silencing – *p < 0.05 between control and 
overexpression).. (D) Western blot analysis shows a decrease in active (dephosphorylated) ȕ-catenin (92 
kDa) and increased phosphorylated CamKII (50 kDa) at day 14 (D14) and D21 in MC3T3-E1 cells in 
which Frzb is stably knocked down (FrzbKD) compared to controls. (E) mRNA expression levels of 
Osterix (2-way ANOVA p < 0.0001 for interaction between time and Frzb silencing – *p < 0.05 between 
control and silencing), Osteocalcin (2-way ANOVA p < 0.0001 for interaction between time and Frzb 
silencing – *p < 0.05 between control and silencing)) and Axin2 in FrzbKD cells with loss of Frzb. mRNA 
levels were normalized to Hprt1 (reference gene) and shown as relative expression levels compared to 
control (D1). Data (A-E) show mean±SD of three replicates, but similar data were obtained in two 
additional experiments and for two other, independent cell lines with loss of Frzb..
Figure 4: Positive effect of Frzb on osteogenesis in hPDCs and hBMSCs. (left) Alizarin red (AR) 
staining of hPDCs and hBMSCs treated with conditioned medium (CM) of MC3T3-E1 cells stably 
overexpressing the control or Frzb+ construct at day 28 (D28). (right) Quantification of the AR staining. 
Data are expressed as the percentage (%) of the area that is covered by mineralised nodules. Data are 
shown as mean±SD of three (hPDCs) or six (hBMSCs) independent replicates. Unpaired t-test *p=0.03 
and *p=0.02.
Figure 5: FrzbCRD and FrzbNTN domain have different effects on osteogenesis. (A) Alizarin red (AR) 
staining of MC3T3-E1 cells with overexpressing FrzbNTN (FrzbNTN+) compared to controls. (B) AR 
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staining of hBMSCs cells treated with conditionned medium (CM) of MC3T3-E1 cells stably 
overexpressing the control or FrzbNTN+ construct at day 28 (D28) and quantification thereof. Data (B) are 
expressed as the percentage (%) of the area that is covered by mineralised nodules. Data are shown as 
mean±SD of six independent replicates. Unpaired t-test *p=0.01 (C) Quantification of the AR staining. 
Data are expressed as relative absorbance compared to control cells at the same timepoint. (2-way 
ANOVA p < 0.0001 for interaction between time and Frzb overexpression – *p < 0.05 between control 
and overexpression) (D) Alkaline phosphatase (AP) activity of FrzbNTN+ cells compared to controls. (2-
way ANOVA *p < 0.0001 for interaction between time and Frzb overexpression – *p < 0.05 between 
control and overexpression) (E) mRNA expression levels of Osterix at day 1 (D1) and D7. (2-way 
ANOVA p = 0.0359 for interaction between time and Frzb overexpression – *p < 0.05 between control 
and overexpression)) (F) AR staining of MC3T3-E1 cells overexpressing FrzbCRD (FrzbCRD+) compared to 
controls. (G) AR staining of hBMSCs cells treated with conditionned medium (CM) of MC3T3-E1 cells 
stably overexpressing the control or FrzbCRD+ construct at day 28 (D28) and quantification thereof. Data 
are expressed as the percentage (%) of the area that is covered by mineralised nodules. Data are shown as 
mean±SD of six independent replicates. Unpaired t-test *p<0.0001. (H) Quantification of the AR staining. 
(2-way ANOVA p = 0.0007 for interaction between time and Frzb overexpression – *p < 0.05 between 
control and overexpression)) (I) AP activity of FrzbCRD+ cells compared to controls at different time 
points. (2-way ANOVA p < 0.0001 for interaction between time and Frzb overexpression – *p < 0.05 
between control and overexpression)) (J) mRNA expression levels of Osterix at D1 and D7. mRNA levels 
were normalized to Hprt1 (reference gene) and shown as relative expression levels compared to control 
(D1). Data (A, C-F, H-J) show mean±SD of three replicates, but similar data were obtained in two 
additional experiments and for two other, independent cell lines with loss of Frzb.. 
Figure 6: Both FrzbCRD and FrzbNTN overexpression decrease canonical Wnt signaling. (A) Western 
blot analysis shows a decrease in active (dephosphorylated) ȕ-catenin (92 kDa) and a decrease in 
phosphorylated CamKII (50 kDa) in FrzbNTN overexpressing cells at day 21 (B) Western blot analysis 
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shows a decrease in active (dephosphorylated) ȕ-catenin (92 kDa) and an increase in phosphorylated 
CamKII (50 kDa) in FrzbCRD overexpressing cells at day 21.  
 
 
 






TABLES 
 
Table 1. Primer sequences  
 
 Forward primer (5’-3’) Reverse primer (5’-3’) 
bFrzb GCATTCCCCTGTGCAAGT GAGCAGTTCGAAGGTCTGCT 
mFrzb AGCCCTGCAAGTCTGTGTGT 
 
CCCCTCTGCAGTGTCCAGTA 
mOsterix ATGGCGTCCTCTCTGCTTGA AGTCCCGCAGAGGGCTAGAG 
mOsteocalcin AAGCAGGAGGGCAATAAGGT CAGGGTTAAGCTCACACTGCTC 
mAxin2 CCACCGCGAGTGTGAGAT ACATAGCCGGAACCTACGTG  
mHprt1 TGCTGACCTGCTGGATTACA TAGTCAGTTGCCCCCTGTAT 
 
 
 



